Dr. Eric Verdin, President and CEO of the Buck Institute for Research on Aging, is also a professor of medicine at University of California, San Francisco, and his name appears on over two hundred research papers and fifteen patents. He studies the effects of small molecules, diet, and metabolism on histone deacetylases and sirtuins, which affect aging.
He is among the top 1 percent of cited scientists and has received a Glenn Award for Research in Biological Mechanisms of Aging and a senior scholarship from the Ellison Medical Foundation. Dr. Verdin has extensive experience working with biotech companies. He founded Acylin, which has since been purchased by Abbvie, and he has served on the scientific advisory boards of Elixir, Sirtris, and the well-known Google holding Calico.
Dr. Verdin has also consulted for multiple biotech companies, including Novartis, GSK, J&J, Altana, Roche, and Pfizer. His scientific memberships include the American Association for the Advancement of Science, the American Society for Clinical Investigation, and the Association of American Physicians, and he is on the advisory council of the National Institute on Drug Abuse at the National Institutes of Health.